Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Brief Summary: This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.


Options:
A: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
B: Arm Label: Arm I (carboplatin and paclitaxel); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm II (oxaliplatin and capecitabine); Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Other: Laboratory Biomarker Analysis, Drug: Oxaliplatin, Other: Quality-of-Life Assessment | Arm Label: Arm III (carboplatin, paclitaxel, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm IV (oxaliplatin, capecitabine, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Capecitabine, Other: Laboratory Biomarker Analysis, Drug: Oxaliplatin, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm II (oxaliplatin and capecitabine), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm III (carboplatin, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm II (oxaliplatin and capecitabine), Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Arm II (oxaliplatin and capecitabine), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm III (carboplatin, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm II (oxaliplatin and capecitabine), Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab)
C: Arm Label: Mirvetuximab Soravtansine; Type: EXPERIMENTAL; Interventions: Drug: Mirvetuximab soravtansine | Arm Label: Investigator's Choice (IC) Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Pegylated liposomal doxorubicin, Drug: Topotecan | Intervention Type: DRUG; Name: Mirvetuximab soravtansine; Assigned to Arm(s): Mirvetuximab Soravtansine | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1

Answer: C